ClinicalTrials.Veeva

Menu
U

Universitätsklinikum Freiburg | Klinik fur Dermatologie und Venerologie

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Obinutuzumab
Lenalidomide
Dasatinib
Carboplatin
Atezolizumab
Dexamethasone
LX211
Docetaxel
Octreotide
5-Fluorouracil

Parent organization

This site is a part of Universitätsklinikum Freiburg

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

37 of 174 total trials

"InDACtion" vs "3+7" Induction in AML

Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the treatment of elderly AML patients wi...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: standard combination chemotherapy
Drug: decitabine

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), includ...

Enrolling
SM With an Associated Hematologic Neoplasm (SM-AHN)
Aggressive Systemic Mastocytosis (ASM)
Drug: bezuclastinib

The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung dise...

Enrolling
Chronic Lung Disease of Prematurity
Intraventricular Hemorrhage
Drug: OHB-607

This is an open label, single arm, interventional, prospective first in human study, designed to evaluate the safety of the NAO.VNS SYSTEM.

Enrolling
Drug Resistant Epilepsy
Device: VNS Treatment

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Bas...

Active, not recruiting
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Drug: Placebo
Drug: HZN-825 QD

The primary efficacy objective:To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.The secondary effic...

Active, not recruiting
Idiopathic Inflammatory Myositis
Drug: Daxdilimab
Drug: Placebo

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and o...

Active, not recruiting
Follicular Lymphoma
Drug: Obinutuzumab
Drug: Copanlisib

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medi...

Begins enrollment this month
Diabetes Mellitus, Type 2
Drug: Cagrilintide
Drug: Semaglutide

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling
Type 2 Diabetes
Drug: Semaglutide
Drug: Cagrilintide

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

This study will be comprised of 2 parts: Part 1 (dose escalation) will be conducted to evaluate the safety and tolerability of 2 doses (100 milligram...

Active, not recruiting
Muscular Dystrophy, Duchenne
Drug: Eteplirsen

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of N...

Active, not recruiting
Lupus Nephritis
Drug: Placebo
Drug: MMF

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of RO7303509 treatment in participants with systemic scl...

Active, not recruiting
Systemic Sclerosis
Drug: RO7303509
Drug: Placebo

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM202...

Active, not recruiting
Acromegaly
Drug: CAM2029 (octreotide subcutaneous depot)

Primary objective: To estimate the efficacy of adjuvant nivolumab monotherapy in completely resected MCC patientsPrimary endpoint: Disease-free survi...

Active, not recruiting
Merkel Cell Carcinoma
Drug: Nivolumab

The MINERVA Trial aims to evaluate safety, efficacy and quality of life (QoL) for the combination of Abemaciclib with an Aromatase Inhibitor or Fulve...

Enrolling
HER2-negative Metastatic Breast Cancer
Hormone Receptor-positive Metastatic Breast Cancer
Drug: Abemaciclib + Aromatase Inhibitor
Drug: Abemaciclib + Fulvestrant

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monothe...

Enrolling
Low-grade Glioma
Drug: Tovorafenib
Drug: Chemotherapeutic Agent

The purpose of this study is to obtain clinical outcome data on safety and effectiveness of the directSTIM DBS system when used on-label, according t...

Enrolling
Parkinson Disease
Procedure: Deep Brain Stimulation

Trial sponsors

Boehringer Ingelheim logo
U
Lilly logo
I
Bayer logo
Genentech logo
L
J
U
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems